Literature DB >> 21926463

Loss of memory B cells during chronic HIV infection is driven by Foxo3a- and TRAIL-mediated apoptosis.

Julien van Grevenynghe1, Rafael A Cubas, Alessandra Noto, Sandrina DaFonseca, Zhong He, Yoav Peretz, Abdelali Filali-Mouhim, Franck P Dupuy, Francesco A Procopio, Nicolas Chomont, Robert S Balderas, Elias A Said, Mohamed-Rachid Boulassel, Cecile L Tremblay, Jean-Pierre Routy, Rafick-Pierre Sékaly, Elias K Haddad.   

Abstract

Loss of memory B cells occurs from the onset of HIV-1 infection and persists into the chronic stages of infection. Lack of survival of these cells, even in subjects being treated, could primarily be the consequence of an altered local microenvironment induced by HIV infection. In this study we showed that memory B cell survival was significantly decreased in aviremic successfully treated (ST) subjects compared with subjects who control viral load as a result of natural immunity (elite controller [EC]) or with uninfected control (HIV-) subjects. The lower survival levels observed in memory B cells from ST subjects were the result of disrupted IL-2 signaling that led to increased transcriptional activity of Foxo3a and increased expression of its proapoptotic target TRAIL. Notably, memory B cell survival in ST subjects was significantly enhanced by the addition of exogenous IL-2 in a Foxo3a-dependent manner. We further showed that Foxo3a silencing by siRNA resulted in decreased expression of TRAIL and apoptosis levels in memory B cells from ST subjects. Our results thus establish a direct role for Foxo3a/TRAIL signaling in the persistence of memory B cells and provide a mechanism for the reduced survival of memory B cells during HIV infection. This knowledge could be exploited for the development of therapeutic and preventative HIV vaccines.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21926463      PMCID: PMC3195482          DOI: 10.1172/JCI59211

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  61 in total

1.  Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor.

Authors:  A Brunet; A Bonni; M J Zigmond; M Z Lin; P Juo; L S Hu; M J Anderson; K C Arden; J Blenis; M E Greenberg
Journal:  Cell       Date:  1999-03-19       Impact factor: 41.582

Review 2.  Role of pro-inflammatory cytokines and beta-chemokines in controlling HIV replication.

Authors:  E Vicenzi; P Biswas; M Mengozzi; G Poli
Journal:  J Leukoc Biol       Date:  1997-07       Impact factor: 4.962

3.  Apoptosis of CD4+ and CD19+ cells during human immunodeficiency virus type 1 infection--correlation with clinical progression, viral load, and loss of humoral immunity.

Authors:  A Samuelsson; C Broström; N van Dijk; A Sönnerborg; F Chiodi
Journal:  Virology       Date:  1997-11-24       Impact factor: 3.616

4.  Evidence for a large compartment of IgM-expressing memory B cells in humans.

Authors:  U Klein; R Küppers; K Rajewsky
Journal:  Blood       Date:  1997-02-15       Impact factor: 22.113

5.  Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection.

Authors:  Y Cao; L Qin; L Zhang; J Safrit; D D Ho
Journal:  N Engl J Med       Date:  1995-01-26       Impact factor: 91.245

6.  Human blood IgM "memory" B cells are circulating splenic marginal zone B cells harboring a prediversified immunoglobulin repertoire.

Authors:  Sandra Weller; Moritz C Braun; Bruce K Tan; Andreas Rosenwald; Corinne Cordier; Mary Ellen Conley; Alessandro Plebani; Dinakhanta S Kumararatne; Damien Bonnet; Olivier Tournilhac; Gil Tchernia; Birte Steiniger; Louis M Staudt; Jean-Laurent Casanova; Claude-Agnès Reynaud; Jean-Claude Weill
Journal:  Blood       Date:  2004-06-10       Impact factor: 22.113

7.  B cell activation during HIV-1 infection. II. Cell-to-cell interactions and cytokine requirement.

Authors:  A Amadori; R Zamarchi; M L Veronese; M Panozzo; A Barelli; A Borri; M Sironi; F Colotta; A Mantovani; L Chieco-Bianchi
Journal:  J Immunol       Date:  1991-01-01       Impact factor: 5.422

8.  Selective CD27+ (memory) B cell reduction and characteristic B cell alteration in drug-naive and HAART-treated HIV type 1-infected patients.

Authors:  Yong Chong; Hideyuki Ikematsu; Kensuke Kikuchi; Masahiro Yamamoto; Masayuki Murata; Mika Nishimura; Shigeki Nabeshima; Seizaburo Kashiwagi; Jun Hayashi
Journal:  AIDS Res Hum Retroviruses       Date:  2004-02       Impact factor: 2.205

9.  Mechanisms of hypergammaglobulinemia and impaired antigen-specific humoral immunity in HIV-1 infection.

Authors:  Angelo De Milito; Anna Nilsson; Kehmia Titanji; Rigmor Thorstensson; Elisabet Reizenstein; Mitsuo Narita; Sven Grutzmeier; Anders Sönnerborg; Francesca Chiodi
Journal:  Blood       Date:  2003-11-06       Impact factor: 22.113

10.  Specific antibody production by blood B cells is retained in late stage drug-naïve HIV-infected Africans.

Authors:  Lydie Béniguel; Evelyne Bégaud; Fabrice Cognasse; Philippe Gabrié; Christophe D Mbolidi; Mary A Marovich; Céline Cazorla; Frédéric Lucht; Christian Genin; Olivier Garraud
Journal:  Clin Dev Immunol       Date:  2004-06
View more
  56 in total

Review 1.  The role of cytokines in the pathogenesis and treatment of HIV infection.

Authors:  Marta Catalfamo; Cecile Le Saout; H Clifford Lane
Journal:  Cytokine Growth Factor Rev       Date:  2012-06-26       Impact factor: 7.638

2.  Kynurenine Reduces Memory CD4 T-Cell Survival by Interfering with Interleukin-2 Signaling Early during HIV-1 Infection.

Authors:  Xavier Dagenais-Lussier; Mouna Aounallah; Vikram Mehraj; Mohamed El-Far; Cecile Tremblay; Rafick-Pierre Sekaly; Jean-Pierre Routy; Julien van Grevenynghe
Journal:  J Virol       Date:  2016-08-12       Impact factor: 5.103

Review 3.  The dysfunction of T follicular helper cells.

Authors:  Rafael Cubas; Matthieu Perreau
Journal:  Curr Opin HIV AIDS       Date:  2014-09       Impact factor: 4.283

Review 4.  Molecular and genetic inflammation networks in major human diseases.

Authors:  Yongzhong Zhao; Christian V Forst; Camil E Sayegh; I-Ming Wang; Xia Yang; Bin Zhang
Journal:  Mol Biosyst       Date:  2016-07-19

5.  TRAILshort Protects against CD4 T Cell Death during Acute HIV Infection.

Authors:  Sekar Natesampillai; Ana C Paim; Nathan W Cummins; Aswath P Chandrasekar; Gary D Bren; Sharon R Lewin; Hans-Peter Kiem; Andrew D Badley
Journal:  J Immunol       Date:  2019-06-12       Impact factor: 5.422

Review 6.  Does persistent HIV replication explain continued lymphoma incidence in the era of effective antiretroviral therapy?

Authors:  Jennifer Totonchy; Ethel Cesarman
Journal:  Curr Opin Virol       Date:  2016-09-23       Impact factor: 7.090

7.  Inadequate T follicular cell help impairs B cell immunity during HIV infection.

Authors:  Rafael A Cubas; Joseph C Mudd; Anne-Laure Savoye; Matthieu Perreau; Julien van Grevenynghe; Talibah Metcalf; Elizabeth Connick; Amie Meditz; Gordon J Freeman; Guillermo Abesada-Terk; Jeffrey M Jacobson; Ari D Brooks; Shane Crotty; Jacob D Estes; Giuseppe Pantaleo; Michael M Lederman; Elias K Haddad
Journal:  Nat Med       Date:  2013-03-10       Impact factor: 53.440

Review 8.  Foxo3a: an integrator of immune dysfunction during HIV infection.

Authors:  Julien van Grevenynghe; Rafael A Cubas; Sandrina DaFonseca; Talibah Metcalf; Cecile L Tremblay; Lydie Trautmann; Rafick-Pierre Sekaly; John Schatzle; Elias K Haddad
Journal:  Cytokine Growth Factor Rev       Date:  2012-06-27       Impact factor: 7.638

Review 9.  Role of IL-21 and IL-21 receptor on B cells in HIV infection.

Authors:  Suresh Pallikkuth; Anita Parmigiani; Savita Pahwa
Journal:  Crit Rev Immunol       Date:  2012       Impact factor: 2.214

Review 10.  Immune activation and HIV persistence: implications for curative approaches to HIV infection.

Authors:  Nichole R Klatt; Nicolas Chomont; Daniel C Douek; Steven G Deeks
Journal:  Immunol Rev       Date:  2013-07       Impact factor: 12.988

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.